Lexicon Pharma (LXRX) Misses Q2 EPS by 2c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
- SeaStar Medical (ICU) Misses Q1 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
